Nanobiotix shares surge 14.61% intraday after regulatory reclassification and patent filing for JNJ-1900 NBTXR3.

Nanobiotix S.A. surged 14.61% intraday as European health authorities reclassify JNJ-1900 NBTXR3 from a medical device to a drug, aligning with major market regulations and simplifying global approval processes. Additionally, the company filed a new patent application for JNJ-1900, enhancing intellectual property protection and market exclusivity. Nanobiotix focuses on innovative radiotherapy enhancement technologies, with its core product NBTXR3 physically enhancing tumor radiotherapy effects, compatible with standard treatments and covering multiple cancer types.